The Script – CELLSCRIPT’s Blog

How the Moderna/Merck Phase 3 Trial Success Could Transform mRNA Vaccines into Personalized Medicines

Author: Anthony Person, Ph.D. Director of Business Development at CELLSCRIPT™    The recent Phase 3 success of INTerpath-001, the pivotal trial evaluating Moderna and Merck’s personalized cancer vaccine intismeran autogene (mRNA-4157/V940) in combination with Keytruda, may represent one of the most important milestones in the evolution of mRNA technology since the COVID-19 pandemic. The trial demonstrated [...]

Read More... from How the Moderna/Merck Phase 3 Trial Success Could Transform mRNA Vaccines into Personalized Medicines

Why Your mRNA Is Underperforming: The dsRNA Problem Most Workflows Aren’t Solving.

If your in vitro transcribed mRNA is producing lower yields, inconsistent results between batches, or immune activation you didn’t design for, there’s a reasonable chance you’ve already ruled out the obvious causes. Reagent lot, transfection efficiency, cell health, construct design — most labs work through that list before they get anywhere near the IVT reaction [...]

Read More... from Why Your mRNA Is Underperforming: The dsRNA Problem Most Workflows Aren’t Solving.

Sample Product(x1) added to cart

Cellscript Menu